Jennitte Stevens

Jennitte brings an impressive track record in therapeutic discovery, design and development at Amgen. Jennitte will spearhead how insitro continues to build a unique research and preclinical engine that incorporates both experimental and computational technologies to generate a pipeline of differentiated therapeutics. 

For close to two decades, Jennitte was closely involved in advancing a range of Amgen’s novel technologies and modalities, including biologics, synthetics, cell therapies and oligonucleotides. In total, she supported 100+ therapeutic programs, including 30+ IND submissions and 10 BLAs. She has more than 40+ publications and multiple patents to her name and was recognized for the development and use of cutting-edge technologies to improve efficiency and shorten timelines.

Jennitte was previously an Executive Director in Process Development at Amgen, having first joined Amgen in 2005 in the Protein Sciences Department in Discovery Research, with a focus on advancing protein expression technologies, protein engineering and molecule assessment. She was instrumental in advancing Amgen’s CHO expression platforms and implementation of cutting-edge technologies to improve efficiency and shorten timelines, winning 2 gold medals and 1 silver medal Amgen Innovation awards, and author on over 40 publications and an inventor on multiple patents. She also led a Pre-Pivotal Process Development organization, managing teams that have advanced therapeutics modalities such as biologics, synthetics, cell therapies and oligonucleoties to the clinic.

Prior to Amgen, Jennitte worked at AmCyte (Santa Monica, CA) focusing on stem cell culture and differentiation toenable pancreatic islet cell therapies. Jennitte earned her Ph.D. at UCLA in the Molecular Biology Institute (MBI) inthe laboratory of Dr. Arnie Berk, studying mechanisms of transcriptional activation in mammalian cells that lead tothe identification of the mammalian mediator complex.